Clinical trials: Endometrioid Ovarian Cancer
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status
This is a non-randomized, open-label study to assess olaparib tablets as a treatment for subjects with different homologous recombination deficiency (HRD) tumor status and with platinum-sensitive, relapsed, high-grade serous or…
- Trial name
- NCT02983799
- Testing
- OLAPARIB
- Where
- 47 sites in United States, Canada
- Volunteers
- 272 people
- Sponsor
- AstraZeneca
Advanced Solid Tumor, Ovarian Cancer
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
The purpose of the dose escalation phase is to evaluate the safety profile of escalating doses and dose schedules of NXP800. In the expansion phase the preliminary efficacy in subjects with ARID1a mutated ovarian clear cell and…
- Conditions
- Advanced Solid Tumor, Ovarian Cancer, Ovarian Clear Cell Carcinoma, Ovarian Clear Cell Tumor
- Trial name
- NCT05226507
- Testing
- NXP800
- Where
- 22 sites in United States, United Kingdom
- Volunteers
- 45 people
- Sponsor
- Nuvectis Pharma, Inc.
Ovarian Cancer, Ovarian Neoplasms
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
This study, ELU- FRα-1, was focused on adult subjects who have advanced, recurrent or refractory folate receptor alpha (FRα) overexpressing tumors considered to be topoisomerase 1 inhibitor-sensitive based on scientific…
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Endometrial Cancer
- Trial name
- NCT05001282
- Testing
- ELU001
- Where
- 18 sites in United States
- Volunteers
- 79 people
- Sponsor
- Elucida Oncology
Ovarian Cancer
Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients
A research study evaluating a new oncolytic virus, THEO-260, in patients with advanced ovarian cancer. The trial will investigate different doses of THEO-260 administered by the intraperitoneal route to identify a dose that is…
- Trial name
- OCTOPOD-IP (NCT07211659)
- Testing
- THEO-260
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Theolytics Limited
Peritoneal Carcinomatosis, Ovarian Cancer
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
This is a Phase 2, controlled, randomised, parallel assignment, open label, multicentre study to evaluate efficacy and safety of a single intraperitoneal injection of Radspherin® in patients with primary advanced high-grade…
- Trial name
- NCT06504147
- Testing
- Radspherin
- Where
- 10 sites in United States, Belgium and 4 more
- Volunteers
- 114 people
- Sponsor
- Oncoinvent Solutions AS
Endometrial Cancer
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.
- Trial name
- NCT06463028
- Testing
- Sapanisertib, Serabelisib, Paclitaxel
- Where
- 18 sites in United States
- Volunteers
- 40 people
- Sponsor
- Faeth Therapeutics
Fallopian Tube Cancer, Primary Peritoneal Cancer
A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)
The primary purpose of the study is to evaluate the efficacy of R-DXd with or without bevacizumab as maintenance therapy compared with standard of care (SOC) in participants with platinum-sensitive ovarian cancer (PSOC) as…
- Conditions
- Fallopian Tube Cancer, Primary Peritoneal Cancer, High-Grade Serous Ovarian Cancer, Endometrioid Epithelial Ovarian
- Trial name
- NCT07791732
- Testing
- R-DXd, Bevacizumab
- Volunteers
- 600 people
- Sponsor
- Daiichi Sankyo
Cancer
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00101972
- Testing
- monoclonal antibody RAV12
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- MacroGenics
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with gene therapy using SCH-58500 may kill more tumor cells.
- Trial name
- NCT00003880
- Testing
- recombinant adenovirus-p53 SCH-58500, carboplatin, paclitaxel
- Volunteers
- 132 people
- Sponsor
- Merck Sharp & Dohme LLC
Ovarian Neoplasms, Ovarian Epithelial Cancer
Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma
The purpose of this study is to determine whether DCVAC/OvCa added to chemotherapy (carboplatin plus paclitaxel as first line chemotherapy) may result in prolongation of progression free survival (PFS).
- Trial name
- NCT02107937
- Testing
- DCVAC/OvCa with Standard of Care, DCVAC/OvCa sequentially chemotherapy, Standard of Care
- Where
- 13 sites in Czechia, Poland
- Volunteers
- 136 people
- Sponsor
- SOTIO a.s.
Ovarian Cancer Recurrent
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
Researchers are looking for other ways to treat high-grade serous and certain other ovarian cancer. High-grade means the cancer cells grow and spread quickly.
- Trial name
- NCT06843447
- Testing
- Raludotatug Deruxtecan, Carboplatin, Paclitaxel
- Where
- 40 sites in United States, Australia and 7 more
- Volunteers
- 605 people
- Sponsor
- Merck Sharp & Dohme LLC
Relapsed/Refractory Ovarian Carcinoma
Study of NTB-928 in R/R OC
The goal of this clinical trial is to determine if NTB-928 can be given safely to adult females with ovarian cancer that has come back (relapsed) or stopped responding to treatment (refractory), how NTB-928 moves through the…
- Trial name
- NCT07690189
- Testing
- NTB-928
- Where
- 4 sites in United States
- Volunteers
- 90 people
- Sponsor
- TeneoSeven, Inc.
Epithelial Ovarian Cancer, Fallopian Tube Cancer
A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
This is an open label Phase 2, 2-stage, 2-cohort study to evaluate rucaparib in combination with nivolumab in patients with high-grade serous or endometroid ovarian cancer.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, High Grade Serous Carcinoma
- Trial name
- NCT03824704
- Testing
- Rucaparib, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- pharmaand GmbH